SATEEN · CL02-ORY-2001MS
Public neurological clinical research study information. Check the current recruitment status in the live Wix study record.
A randomized, double-blind, placebo-controlled, three-arm parallel-group study lasting 36 weeks to evaluate the safety and tolerability of ORY-2001 in patients with relapsing-remitting or secondary progressive multiple sclerosis. EudraCT: 2017-002838-23.
Sponsor: ORYZON
Phase: II
Area: Neuroimmunology